MK 852

Drug Profile

MK 852

Alternative Names: L 367073

Latest Information Update: 15 Feb 1995

Price : $50

At a glance

  • Originator Merck & Co
  • Class
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombosis; Unstable angina pectoris

Most Recent Events

  • 15 Feb 1995 Discontinued-II for Thrombosis in USA (IV-injection)
  • 15 Feb 1995 Discontinued-II for Thrombosis in USA (PO)
  • 15 Feb 1995 Discontinued-II for Unstable angina pectoris in USA (IV-injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top